RSV (respiratory syncytial virus) prevention: cross-border specialty drug access for international patients

Quick orientation

RSV is among the leading causes of hospitalization in infants under 12 months globally. RSV in older adults is also a substantial respiratory illness burden.

Typical age of onset. Infants of all ages are at risk; high-risk groups include premature infants and those with congenital heart or lung disease. Older adults with comorbidities are also at elevated risk.

Severity tiers. Severity ranges from mild upper respiratory infection to severe bronchiolitis requiring hospitalization.

Why specialty drugs for RSV (respiratory syncytial virus) prevention are hard to access internationally

Long-acting RSV monoclonal antibodies for infants (nirsevimab, clesrovimab) and RSV vaccines for older adults and pregnant women are recent additions. International registration varies and supply has been intermittent during peak demand periods.

Treatments approved by the FDA

• Enflonsia (clesrovimab-cfor) — FDA approval: 2025. Mechanism: Long-acting anti-RSV monoclonal antibody for infants. Route: Intramuscular injection (single dose typically). US WAC ballpark: Approximately USD 500 per dose. Country pricing: Jordan · Bahrain · Oman.
• Yeztugo (lenacapavir, HIV-prevention representative product) — FDA approval: 2025. Mechanism: Long-acting HIV-1 capsid inhibitor (listed here for completeness of prevention catalog; not RSV-specific). Route: Subcutaneous injection every 6 months. US WAC ballpark: Approximately USD 28,000 per year. Country pricing: India · Bahrain · Oman.

Cross-border pathways used for RSV (respiratory syncytial virus) prevention

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm eligibility based on age, prematurity, and comorbidities.
• Document RSV season timing in destination country.
• Cold-chain handling is critical for monoclonal antibodies and vaccines.
• Coordinate with pediatrician or treating physician.

Common questions

Is Enflonsia available in my country?

Registration is rolling out. We confirm by destination.

Should my infant receive an RSV product?

Eligibility depends on age, prematurity, and risk factors. Your pediatrician decides.

Can a single dose protect the whole season?

Long-acting products are designed to provide season-long protection in most infants. Specific dosing follows the label.

How is the cold chain handled?

Validated specialty couriers with continuous temperature monitoring.

What documents are required?

Pediatrician's prescription, vaccination and product history, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For RSV (respiratory syncytial virus) prevention, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for RSV (respiratory syncytial virus) prevention

Reserved for you.